罗格列酮对2型糖尿病患者血清抵抗素水平的影响

Effect of rosiglitazone on resistin level in patients with type 2 diabetes

目的研究罗格列酮(ROS)对2型糖尿病患者血清抵抗素(Resistin)水平的影响。方法符合1999年WHO糖尿病诊断标准的初诊2型糖尿病患者38例,均给予口服ROS 4 mg,每日1次,总疗程4周,测定指标包括一般项目、血糖和血清胰岛素及抵抗素,以HOMA模型评价组织胰岛素敏感性。结果ROS治疗4周后,患者空腹血糖、血清胰岛素水平及胰岛素抵抗指数(HOMA-IR)明显降低(P<0.01或P<0.05),而体重指数(BMI)及腰臀比(WHR)明显增加(P<0.05);血清抵抗素水平前后比较差异无统计学意义(P>0.05)。Pearson相关性分析显示,2型糖尿病患者血清抵抗素水平与体重指数、腰臀比和HOMA-IR等无关(P>0.05)。结论ROS能显著降低2型糖尿病患者胰岛素抵抗程度,改善糖代谢,但对人血清抵抗素水平无明显影响。

Objective To study the effect of rosiglitazone（ROS） on resistin level in patients with type 2 diabetes. Methods Thirty-eight patients with type 2 diabetes meUitus were recruited according to WHO criterion （1999）. Self-pair trial was used and each patient was orally given ROS 4 mg each day for 4 weeks. Clinical routine and plasma glucose, insulin and resistin determination were performed. Insulin sensitivity was evaluated using homeostasis model assessment（HOMA） formula. Results Levels of fasting plasma glucose, insulin and HOMA-IR were significantly decreased（ P 〈 0.01 or P 〈0.05）, whereas the values of BMI and WHR increased significantly（P〈0.05）after 4 week ROS treatment. The levels of resistin before and after treatment had no significant difference. Notably, the level of serum resistin in patients with type 2 diabetes has no significant correlation with BMI, WHR and HOMA-IR（Pearson correlation analysis, P 〉0.05）. Conclusion ROS can significantly reduce insulin resistance, improve the utilizing of plasma glucose, nevertheless has a little effect on level of resistin in patients with type 2 diabetes.